MA30393B1 - Procede de traitement, de diagnostic ou de detection du cancer - Google Patents
Procede de traitement, de diagnostic ou de detection du cancerInfo
- Publication number
- MA30393B1 MA30393B1 MA31346A MA31346A MA30393B1 MA 30393 B1 MA30393 B1 MA 30393B1 MA 31346 A MA31346 A MA 31346A MA 31346 A MA31346 A MA 31346A MA 30393 B1 MA30393 B1 MA 30393B1
- Authority
- MA
- Morocco
- Prior art keywords
- diagnosing
- treating
- detecting cancer
- methods
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne, entre autres choses, des procédés de traitement du cancer, des compositions de traitement du cancer et des procédés et compositions de diagnostic et/ou de dtection du cancer. En particulier, la présente invention concerne des compositions et des procédés de traitement, de diagnostic et de détection des cancers associés à une surexpression de LIV-1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79187106P | 2006-04-13 | 2006-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30393B1 true MA30393B1 (fr) | 2009-05-04 |
Family
ID=38610188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31346A MA30393B1 (fr) | 2006-04-13 | 2008-11-03 | Procede de traitement, de diagnostic ou de detection du cancer |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100196377A1 (fr) |
EP (2) | EP2012827A2 (fr) |
JP (1) | JP2009541208A (fr) |
KR (1) | KR20090010194A (fr) |
CN (1) | CN101622273A (fr) |
AU (1) | AU2007238636A1 (fr) |
BR (1) | BRPI0710616A2 (fr) |
CA (1) | CA2650126A1 (fr) |
MA (1) | MA30393B1 (fr) |
MX (1) | MX2008013121A (fr) |
NO (1) | NO20084795L (fr) |
TN (1) | TNSN08401A1 (fr) |
TW (1) | TW200813231A (fr) |
WO (1) | WO2007120787A2 (fr) |
ZA (1) | ZA200808669B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040141983A1 (en) | 1999-03-15 | 2004-07-22 | Protein Design Labs, Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
WO2004067564A2 (fr) | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions contre l'antgene cancereux liv-1 et leurs utilisations |
EP2493916B1 (fr) * | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Marqueurs associés avec des tumeurs pulmonaires et leur utilisation |
RS55843B1 (sr) * | 2010-12-06 | 2017-08-31 | Seattle Genetics Inc | Humanizovana antitela za liv-1 i upotreba istih u lečenju kancera |
MX2016010903A (es) * | 2014-02-27 | 2016-11-18 | Procter & Gamble | Metodo para evaluar zinc biodisponible. |
KR20160045471A (ko) | 2014-10-17 | 2016-04-27 | 대산안전산업 주식회사 | 방풍창이 구비된 방음패널 |
MA45324A (fr) | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique |
EP3717518A1 (fr) * | 2017-12-01 | 2020-10-07 | Seattle Genetics, Inc. | Anticorps anti-liv1 humanisés pour le traitement du cancer du sein |
CN111289756A (zh) * | 2018-12-10 | 2020-06-16 | 北京师范大学 | 卵巢癌肺转移成瘤相关的尿液标志物 |
GB201908208D0 (en) * | 2019-06-10 | 2019-07-24 | Univ College Cardiff Consultants Ltd | An anti-mitotic agent |
WO2021047507A1 (fr) * | 2019-09-09 | 2021-03-18 | 浙江百寿康迪生物医药有限责任公司 | Procédé d'identification d'une substance capable d'affecter le vieillissement |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
WO1981001145A1 (fr) | 1979-10-18 | 1981-04-30 | Univ Illinois | Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US5637677A (en) | 1987-07-16 | 1997-06-10 | The Trustees Of The University Of Pennsylvania | Biologically active compounds and methods of constructing and using the same |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
ATE120454T1 (de) | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
AU654811B2 (en) | 1990-03-20 | 1994-11-24 | Trustees Of Columbia University In The City Of New York, The | Chimeric antibodies with receptor binding ligands in place of their constant region |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
EP0546073B1 (fr) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production et utilisation des animaux non humains transgeniques capable de produire des anticorps heterologues |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
JPH09506761A (ja) | 1990-11-09 | 1997-07-08 | ステファン ディー.ギリーズ | サイトカインの免疫複合体 |
US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
CA2507749C (fr) | 1991-12-13 | 2010-08-24 | Xoma Corporation | Methodes et materiaux pour la preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
AU675661B2 (en) | 1992-07-24 | 1997-02-13 | Abgenix, Inc. | Generation of xenogeneic antibodies |
DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
CA2132500A1 (fr) * | 1994-09-20 | 1996-03-21 | David Lockwood Manning | Methodes pour predire l'evolution des tumeurs du sein |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
EP1978033A3 (fr) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Anticorps humains dérivés à partir de xénosouris immunisée |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
US5830698A (en) | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
US6475220B1 (en) | 1999-10-15 | 2002-11-05 | Whiteside Biomechanics, Inc. | Spinal cable system |
CA2386270A1 (fr) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Genes de voies d'interference d'arn en tant qu'outils d'interference genetique ciblee |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
CA2395832A1 (fr) * | 2000-01-25 | 2001-08-02 | Genentech, Inc. | Compositions et methodes de traitement de cancer |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
US7074175B2 (en) | 2001-07-25 | 2006-07-11 | Erik Schroeder Handy | Thermotherapy via targeted delivery of nanoscale magnetic particles |
WO2003026577A2 (fr) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-aminobenzyl ether dans des agents d'administration de medicaments |
CN1849337A (zh) * | 2003-01-27 | 2006-10-18 | 比奥根艾迪克Ma公司 | 利用igsf9和liv-1的、用于治疗癌症的组合物及方法 |
WO2004067564A2 (fr) * | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions contre l'antgene cancereux liv-1 et leurs utilisations |
CN1956722A (zh) | 2003-05-20 | 2007-05-02 | 伊缪诺金公司 | 含有新的美登素类的改进的细胞毒剂 |
CA2527571A1 (fr) * | 2003-05-29 | 2004-12-09 | Millennium Pharmaceuticals, Inc. | Compositions, kits et procedes d'identification, d'evaluation et de prevention, et therapie anticancereuse |
US20080070836A1 (en) * | 2003-12-26 | 2008-03-20 | Toshio Hirano | Emt-Inducing Agents |
WO2007086915A2 (fr) * | 2005-05-12 | 2007-08-02 | Applied Genomics, Inc. | Reactifs et leurs procedes d’utilisation lors du diagnostic, de la classification et de la therapie de cancers |
-
2007
- 2007-04-12 JP JP2009505486A patent/JP2009541208A/ja active Pending
- 2007-04-12 WO PCT/US2007/009063 patent/WO2007120787A2/fr active Application Filing
- 2007-04-12 KR KR1020087027681A patent/KR20090010194A/ko not_active Application Discontinuation
- 2007-04-12 EP EP07755364A patent/EP2012827A2/fr not_active Withdrawn
- 2007-04-12 US US12/296,833 patent/US20100196377A1/en not_active Abandoned
- 2007-04-12 MX MX2008013121A patent/MX2008013121A/es not_active Application Discontinuation
- 2007-04-12 CA CA002650126A patent/CA2650126A1/fr not_active Abandoned
- 2007-04-12 AU AU2007238636A patent/AU2007238636A1/en not_active Abandoned
- 2007-04-12 EP EP11171117A patent/EP2407483A1/fr not_active Withdrawn
- 2007-04-12 CN CN200780021878A patent/CN101622273A/zh active Pending
- 2007-04-12 TW TW096112880A patent/TW200813231A/zh unknown
- 2007-04-12 BR BRPI0710616-5A patent/BRPI0710616A2/pt not_active IP Right Cessation
-
2008
- 2008-10-10 ZA ZA200808669A patent/ZA200808669B/xx unknown
- 2008-10-13 TN TNP2008000401A patent/TNSN08401A1/en unknown
- 2008-11-03 MA MA31346A patent/MA30393B1/fr unknown
- 2008-11-13 NO NO20084795A patent/NO20084795L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2009541208A (ja) | 2009-11-26 |
CA2650126A1 (fr) | 2007-10-25 |
NO20084795L (no) | 2009-01-13 |
ZA200808669B (en) | 2009-10-28 |
CN101622273A (zh) | 2010-01-06 |
TNSN08401A1 (en) | 2010-04-14 |
US20100196377A1 (en) | 2010-08-05 |
EP2407483A1 (fr) | 2012-01-18 |
AU2007238636A1 (en) | 2007-10-25 |
BRPI0710616A2 (pt) | 2011-08-16 |
WO2007120787A3 (fr) | 2009-04-30 |
MX2008013121A (es) | 2009-03-25 |
KR20090010194A (ko) | 2009-01-29 |
TW200813231A (en) | 2008-03-16 |
EP2012827A2 (fr) | 2009-01-14 |
WO2007120787A2 (fr) | 2007-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30393B1 (fr) | Procede de traitement, de diagnostic ou de detection du cancer | |
TW200512298A (en) | Method of diagnosing breast cancer | |
EA200901550A1 (ru) | Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений | |
EA200970891A1 (ru) | Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы | |
EA200702203A1 (ru) | Способы и нуклеиновые кислоты для анализов клеточных пролиферативных нарушений | |
WO2013033609A3 (fr) | Méthodes et compositions pour le traitement et le diagnostic du cancer | |
EA201400117A1 (ru) | Способы и нуклеиновые кислоты для определения прогноза у больных раком | |
WO2012006589A3 (fr) | Procédés et compositions pour l'identification, l'évaluation et le traitement de cancers associés à des signaux hedgehog | |
MX341926B (es) | Metodos y composiciones para la diagnosis y prognosis de daño renal y falla renal. | |
WO2010033773A3 (fr) | Utilisations diagnostiques, pronostiques et thérapeutiques de mir dans des voies adaptatives et/ou des voies pathologiques | |
WO2009015050A3 (fr) | Profil d'expression génique pour prédire la survie d'une patiente atteinte d'un cancer des ovaires | |
WO2008061020A3 (fr) | Méthodes permettant de traiter, de diagnostiquer ou de détecter un cancer | |
WO2007149948A3 (fr) | Compositions et procédés de diagnostic et de traitement des tumeurs | |
MX336280B (es) | Metodos y composiciones para diagnosticos y pronosticos de lesion renal y falla renal. | |
WO2010033597A3 (fr) | Procédés pour détecter une surexpression de sparc et procédés thérapeutiques et diagnostiques associés à ceux-ci | |
WO2009019370A3 (fr) | Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal | |
MX2009010751A (es) | Composiciones y metodos de deteccion. | |
WO2009139853A3 (fr) | Anticorps monoclonaux humains dirigés contre le récepteur de chimiokines humaines ccr7 | |
MA33091B1 (fr) | Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques | |
AU2010202926B2 (en) | Markers and methods relating to the assessment of Alzheimer's disease | |
EP1951891A4 (fr) | Antigene cancereux mage-a9 et ses utilisations | |
WO2008092002A3 (fr) | Compositions et procédés pour le traitement et le diagnostic du cancer du pancréas | |
MX2009001070A (es) | Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma. | |
BRPI0613970B8 (pt) | composição para o tratamento ou para a prevenção de câncer de cólon compreende uma quantidade farmaceuticamente eficaz de um sirna contra um polinucleotídeo de tom 34 | |
WO2022043930A3 (fr) | Biomarqueurs pour la thérapie anticancéreuse utilisant des antagonistes de mdm2 |